BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19017799)

  • 1. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
    Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
    Krenz M; Yutzey KE; Robbins J
    Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.
    Nakamura T; Colbert M; Krenz M; Molkentin JD; Hahn HS; Dorn GW; Robbins J
    J Clin Invest; 2007 Aug; 117(8):2123-32. PubMed ID: 17641779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
    Nakamura T; Gulick J; Pratt R; Robbins J
    Proc Natl Acad Sci U S A; 2009 Sep; 106(36):15436-41. PubMed ID: 19706403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
    De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
    Edwards MA; Crombie K; Schramm C; Krenz M
    J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.
    Araki T; Chan G; Newbigging S; Morikawa L; Bronson RT; Neel BG
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4736-41. PubMed ID: 19251646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
    Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
    Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
    Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
    Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
    Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
    Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of scaffolding adaptor protein Gab1 with tyrosine phosphatase SHP2 negatively regulates IGF-I-dependent myogenic differentiation via the ERK1/2 signaling pathway.
    Koyama T; Nakaoka Y; Fujio Y; Hirota H; Nishida K; Sugiyama S; Okamoto K; Yamauchi-Takihara K; Yoshimura M; Mochizuki S; Hori M; Hirano T; Mochizuki N
    J Biol Chem; 2008 Aug; 283(35):24234-44. PubMed ID: 18577518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
    Roy R; Krenz M
    J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
    Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
    Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
    J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
    Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
    Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
    Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
    Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.
    Tajan M; Pernin-Grandjean J; Beton N; Gennero I; Capilla F; Neel BG; Araki T; Valet P; Tauber M; Salles JP; Yart A; Edouard T
    Hum Mol Genet; 2018 Jul; 27(13):2276-2289. PubMed ID: 29659837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.
    Levy AD; Xiao X; Shaw JE; Sudarsana Devi SP; Katrancha SM; Bennett AM; Greer CA; Howe JR; Machida K; Koleske AJ
    Cell Rep; 2018 Aug; 24(6):1523-1535. PubMed ID: 30089263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.